Latest Insider Transactions at Rvl Pharmaceuticals PLC (RVLP)
This section provides a real-time view of insider transactions for Rvl Pharmaceuticals PLC (RVLP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of RVL Pharmaceuticals plc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of RVL Pharmaceuticals plc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 20
2023
|
Foundation Harsaul > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,758,899
-49.06%
|
$0
$0.03 P/Share
|
|
Oct 20
2023
|
Altchem LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
4,758,899
-49.06%
|
$0
$0.03 P/Share
|
|
Oct 19
2023
|
Foundation Harsaul > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
9,363,760
-49.12%
|
$0
$0.05 P/Share
|
|
Oct 19
2023
|
Altchem LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
9,363,760
-49.12%
|
$0
$0.05 P/Share
|
|
Oct 18
2023
|
Foundation Harsaul > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,421,537
-15.22%
|
$0
$0.06 P/Share
|
|
Oct 18
2023
|
Altchem LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
3,421,537
-15.22%
|
$0
$0.06 P/Share
|
|
Aug 15
2023
|
Avista Healthcare Partners Gp, Ltd. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
23,730,864
-100.0%
|
-
|
|
Aug 10
2023
|
Alisa Lask Director |
SELL
Payment of exercise price or tax liability
|
Direct |
12,000
-9.63%
|
$0
$0.49 P/Share
|
|
Jul 05
2023
|
Alisa Lask Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+24.31%
|
-
|
|
Jul 05
2023
|
Gregory L Cowan Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+30.76%
|
-
|
|
Jul 05
2023
|
Michael J. De Biasi Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+50.0%
|
-
|
|
May 18
2023
|
James Schaub EVP and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,577
-1.05%
|
$0
$0.87 P/Share
|
|
May 18
2023
|
Christopher Klein General Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
5,447
-2.93%
|
$0
$0.87 P/Share
|
|
Jan 27
2023
|
Avista Capital Partners Iii Gp, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
1,032,995
-100.0%
|
-
|
|
Jan 27
2023
|
Sriram Venkataraman Director |
SELL
Other acquisition or disposition
|
Indirect |
1,032,995
-100.0%
|
-
|
|
Jan 27
2023
|
David F Burgstahler Director |
SELL
Other acquisition or disposition
|
Indirect |
1,032,995
-100.0%
|
-
|
|
Jan 24
2023
|
James Schaub EVP and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,608
-1.78%
|
$9,608
$1.26 P/Share
|
|
Jan 24
2023
|
Christopher Klein General Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
9,608
-4.91%
|
$9,608
$1.26 P/Share
|
|
Aug 10
2022
|
Alisa Lask Director |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+47.01%
|
-
|
|
Aug 08
2022
|
Avista Healthcare Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
8,000,000
+25.21%
|
$8,000,000
$1.55 P/Share
|
|
Aug 08
2022
|
Sriram Venkataraman Director |
BUY
Open market or private purchase
|
Indirect |
8,000,000
+25.21%
|
$8,000,000
$1.55 P/Share
|
|
Aug 08
2022
|
David F Burgstahler Director |
BUY
Open market or private purchase
|
Indirect |
8,000,000
+25.21%
|
$8,000,000
$1.55 P/Share
|
|
Aug 08
2022
|
Brian A Markison Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
850,000
+22.22%
|
$850,000
$1.55 P/Share
|
|
Aug 08
2022
|
James Schaub EVP and COO |
BUY
Open market or private purchase
|
Direct |
150,000
+21.74%
|
$150,000
$1.55 P/Share
|
|
May 18
2022
|
James Schaub EVP and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,273
-1.58%
|
$6,273
$1.4 P/Share
|
|
May 18
2022
|
Christopher Klein General Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
6,127
-3.04%
|
$6,127
$1.4 P/Share
|
|
May 18
2022
|
Tina Marie De Vries EVP, Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
5,447
-3.85%
|
$5,447
$1.4 P/Share
|
|
Jan 24
2022
|
James Schaub EVP and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,607
-2.37%
|
$9,607
$1.13 P/Share
|
|
Jan 24
2022
|
Tina Marie De Vries EVP, Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
9,607
-6.35%
|
$9,607
$1.13 P/Share
|
|
Jan 24
2022
|
Christopher Klein General Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
9,607
-4.55%
|
$9,607
$1.13 P/Share
|
|
Jan 24
2022
|
Andrew J. Einhorn Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,607
-6.36%
|
$9,607
$1.13 P/Share
|
|
Dec 16
2021
|
James Schaub EVP and COO |
BUY
Open market or private purchase
|
Direct |
93,800
+18.77%
|
$93,800
$1.07 P/Share
|
|
Aug 27
2021
|
Fred G Weiss Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5,506
-4.44%
|
$16,518
$3.31 P/Share
|
|
Aug 27
2021
|
Gregory L Cowan Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5,506
-9.91%
|
$16,518
$3.31 P/Share
|
|
Jul 02
2021
|
Fred G Weiss Director |
BUY
Grant, award, or other acquisition
|
Direct |
61,188
+33.05%
|
-
|
|
Jun 18
2021
|
Gregory L Cowan Director |
SELL
Payment of exercise price or tax liability
|
Direct |
18,584
-25.06%
|
$37,168
$2.89 P/Share
|
|
Jun 18
2021
|
Fred G Weiss Director |
SELL
Payment of exercise price or tax liability
|
Direct |
18,584
-22.84%
|
$37,168
$2.89 P/Share
|
|
May 18
2021
|
Tina Marie De Vries EVP, Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
6,467
-4.1%
|
$19,401
$3.12 P/Share
|
|
May 18
2021
|
Andrew J. Einhorn Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,467
-4.1%
|
$19,401
$3.12 P/Share
|
|
May 18
2021
|
Christopher Klein General Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
6,467
-2.97%
|
$19,401
$3.12 P/Share
|
|
May 18
2021
|
James Schaub EVP and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,621
-2.08%
|
$19,863
$3.12 P/Share
|
|
Jan 24
2021
|
Gregory L Cowan Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5,505
-6.91%
|
$22,020
$4.46 P/Share
|
|
Jan 24
2021
|
Fred G Weiss Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5,505
-6.34%
|
$22,020
$4.46 P/Share
|
|
Jan 24
2021
|
Tina Marie De Vries EVP, Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
9,597
-5.74%
|
$38,388
$4.46 P/Share
|
|
Jan 24
2021
|
Andrew J. Einhorn Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,668
-5.78%
|
$38,672
$4.46 P/Share
|
|
Jan 24
2021
|
Christopher Klein General Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
9,605
-4.22%
|
$38,420
$4.46 P/Share
|
|
Jan 24
2021
|
James Schaub EVP and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,687
-2.95%
|
$38,748
$4.46 P/Share
|
|
Nov 20
2020
|
Avista Capital Partners Iii Gp, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
4,936,926
-100.0%
|
-
|
|
Nov 20
2020
|
David F Burgstahler Director |
SELL
Other acquisition or disposition
|
Indirect |
4,936,926
-100.0%
|
-
|
|
Nov 20
2020
|
Sriram Venkataraman Director |
SELL
Other acquisition or disposition
|
Indirect |
4,936,926
-100.0%
|
-
|